We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The mood in Wall Street is upbeat as the S&P 500 has risen 2.2% in the week ending Nov 13. The 30-stock Dow Jones Industrial Average has also rallied more than 4% in the week, hitting an intra-day record (according to a CNBC article).
The recent coronavirus antibody and vaccine development raises hopes of a vaccine soon. On Nov 9, Pfizer (PFE) and BioNTech announced the efficacy of their mRNA-based coronavirus vaccine candidate, BNT162b2. According to the companies, the vaccine was more than 90% successful in preventing COVID-19 in participants without prior evidence of SARS-CoV-2 infection. The results are based on the first interim efficacy analysis conducted on Nov 8, by an external, independent Data Monitoring Committee from the Phase 3 clinical study, per the company. The news has instilled optimism in the market.
Meanwhile, total number of coronavirus cases has crossed 54 million globally. Notably, the world’s largest economy has seen more than 11 million cases alone. Thus, the worsening coronavirus crisis is raising desperation among investors over the introduction of a vaccine.
On the other hand, Eli Lilly and Company (LLY) recently announced that its investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg has been awarded Emergency Use Authorization (EUA) by the FDA.
Moreover, the chances of a divided Congress in the United States seem more likely, where Republicans can continue to control the Senate and Democrats, the House. Thus, as a result of this political gridlock, major and stringent changes in the corporate tax policies will be very difficult to implement in the medium-term. Thus, easing worries regarding major policy changes are making the investing environment more friendly for market participants.
Going on, the United States is pleasantly surprising market participants with upbeat economic data. Notably, the world’s largest economy delivered an impressive performance in third-quarter 2020, beating market expectations. Going by, the Department of Commerce’s report on Oct 29, GDP surged to a record high at an annualized pace of 33.1% after declining 31.4% in the second quarter.
The manufacturing sector is also picking up despite the coronavirus crisis. According to the Institute for Supply Management (ISM) report on Nov 2, its Purchasing Managers' Index (PMI) for manufacturing surged to 59.3% in October, increasing 3.4 points from last month and surpassing the consensus estimate of 55.9%. In fact, the October figure stood out as the highest PMI reading since September 2018.
Furthermore, the housing market continues to be a bright spot in the U.S. economy as it recently delivered a streak of encouraging data. The recently-released data on the U.S. builder confidence was impressive as well. Per the monthly NAHB/Wells Fargo Housing Market Index (HMI), builder confidence for newly-built single-family homes rose to an all-time high of 85 points in October in comparison to 83 points in September, 78 in August and 72 in July. Low interest rates are boosting demand in the housing market and resulting in a rise in mortgage applications.
ETF Strategies to Follow
Here we discus certain ETF strategies to help investors make the most of the upbeat U.S. economic data amid the coronavirus crisis:
Momentum ETFs to Consider
While the broader stock market is expected to gain on optimism surrounding the rebounding U.S. economy and positive developments in coronavirus vaccine research, momentum investing will likely take centerstage as investors seek greater returns in the short term. Momentum investing looks to fetch profits from hot stocks that have shown an uptrend over the past few weeks or months. Investors can consider iShares Edge MSCI USA Momentum Factor ETF (MTUM - Free Report) , Invesco DWA Momentum ETF (PDP - Free Report) , Invesco S&P MidCap Momentum ETF (XMMO), VictoryShares USAA MSCI USA Value Momentum ETF (ULVM) and SPDR Russell 1000 Momentum Focus ETF (ONEO) (read: Here's Why it is the Right Time to Invest in Momentum ETFs).
Growth ETFs to Play
Growth stocks are generally expected to witness a positive revenue and earnings trend at a faster rate than the industry average. As such, growth funds tend to outperform during an uptrend. While there are several options in the growth ETF world, we have highlighted five funds that offer broad-based exposure to the U.S. stock market like Vanguard Growth ETF (VUG - Free Report) , Schwab U.S. Large-Cap Growth ETF (SCHG - Free Report) , iShares Core S&P U.S. Growth ETF (IUSG - Free Report) , SPDR S&P 500 Growth ETF (SPYG) and Vanguard Mega Cap Growth ETF (MGK) (read: Here's Why Growth ETFs Are Sizzling With Opportunities).
Large-Cap ETFs to Look Out For
With the U.S. economy gradually looking up, it makes sense to bet on large-cap ETFs as these funds perform well in such scenarios. Therefore, investors can consider SPDR S&P 500 ETF Trust (SPY - Free Report) , iShares Core S&P 500 ETF (IVV - Free Report) , Vanguard S&P 500 ETF (VOO - Free Report) , Schwab U.S. Large-Cap ETF (SCHX - Free Report) , iShares Russell Top 200 ETF (IWL), Vanguard Mega Cap ETF (MGC) and Multifactor Large Cap ETF (JHML) (read: ETFs Riding the Latest Coronavirus Vaccine Optimism Wave).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ETF Strategies to Gain From US Market Optimism
The mood in Wall Street is upbeat as the S&P 500 has risen 2.2% in the week ending Nov 13. The 30-stock Dow Jones Industrial Average has also rallied more than 4% in the week, hitting an intra-day record (according to a CNBC article).
The recent coronavirus antibody and vaccine development raises hopes of a vaccine soon. On Nov 9, Pfizer (PFE) and BioNTech announced the efficacy of their mRNA-based coronavirus vaccine candidate, BNT162b2. According to the companies, the vaccine was more than 90% successful in preventing COVID-19 in participants without prior evidence of SARS-CoV-2 infection. The results are based on the first interim efficacy analysis conducted on Nov 8, by an external, independent Data Monitoring Committee from the Phase 3 clinical study, per the company. The news has instilled optimism in the market.
Meanwhile, total number of coronavirus cases has crossed 54 million globally. Notably, the world’s largest economy has seen more than 11 million cases alone. Thus, the worsening coronavirus crisis is raising desperation among investors over the introduction of a vaccine.
On the other hand, Eli Lilly and Company (LLY) recently announced that its investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg has been awarded Emergency Use Authorization (EUA) by the FDA.
Moreover, the chances of a divided Congress in the United States seem more likely, where Republicans can continue to control the Senate and Democrats, the House. Thus, as a result of this political gridlock, major and stringent changes in the corporate tax policies will be very difficult to implement in the medium-term. Thus, easing worries regarding major policy changes are making the investing environment more friendly for market participants.
Going on, the United States is pleasantly surprising market participants with upbeat economic data. Notably, the world’s largest economy delivered an impressive performance in third-quarter 2020, beating market expectations. Going by, the Department of Commerce’s report on Oct 29, GDP surged to a record high at an annualized pace of 33.1% after declining 31.4% in the second quarter.
The manufacturing sector is also picking up despite the coronavirus crisis. According to the Institute for Supply Management (ISM) report on Nov 2, its Purchasing Managers' Index (PMI) for manufacturing surged to 59.3% in October, increasing 3.4 points from last month and surpassing the consensus estimate of 55.9%. In fact, the October figure stood out as the highest PMI reading since September 2018.
Furthermore, the housing market continues to be a bright spot in the U.S. economy as it recently delivered a streak of encouraging data. The recently-released data on the U.S. builder confidence was impressive as well. Per the monthly NAHB/Wells Fargo Housing Market Index (HMI), builder confidence for newly-built single-family homes rose to an all-time high of 85 points in October in comparison to 83 points in September, 78 in August and 72 in July. Low interest rates are boosting demand in the housing market and resulting in a rise in mortgage applications.
ETF Strategies to Follow
Here we discus certain ETF strategies to help investors make the most of the upbeat U.S. economic data amid the coronavirus crisis:
Momentum ETFs to Consider
While the broader stock market is expected to gain on optimism surrounding the rebounding U.S. economy and positive developments in coronavirus vaccine research, momentum investing will likely take centerstage as investors seek greater returns in the short term. Momentum investing looks to fetch profits from hot stocks that have shown an uptrend over the past few weeks or months. Investors can consider iShares Edge MSCI USA Momentum Factor ETF (MTUM - Free Report) , Invesco DWA Momentum ETF (PDP - Free Report) , Invesco S&P MidCap Momentum ETF (XMMO), VictoryShares USAA MSCI USA Value Momentum ETF (ULVM) and SPDR Russell 1000 Momentum Focus ETF (ONEO) (read: Here's Why it is the Right Time to Invest in Momentum ETFs).
Growth ETFs to Play
Growth stocks are generally expected to witness a positive revenue and earnings trend at a faster rate than the industry average. As such, growth funds tend to outperform during an uptrend. While there are several options in the growth ETF world, we have highlighted five funds that offer broad-based exposure to the U.S. stock market like Vanguard Growth ETF (VUG - Free Report) , Schwab U.S. Large-Cap Growth ETF (SCHG - Free Report) , iShares Core S&P U.S. Growth ETF (IUSG - Free Report) , SPDR S&P 500 Growth ETF (SPYG) and Vanguard Mega Cap Growth ETF (MGK) (read: Here's Why Growth ETFs Are Sizzling With Opportunities).
Large-Cap ETFs to Look Out For
With the U.S. economy gradually looking up, it makes sense to bet on large-cap ETFs as these funds perform well in such scenarios. Therefore, investors can consider SPDR S&P 500 ETF Trust (SPY - Free Report) , iShares Core S&P 500 ETF (IVV - Free Report) , Vanguard S&P 500 ETF (VOO - Free Report) , Schwab U.S. Large-Cap ETF (SCHX - Free Report) , iShares Russell Top 200 ETF (IWL), Vanguard Mega Cap ETF (MGC) and Multifactor Large Cap ETF (JHML) (read: ETFs Riding the Latest Coronavirus Vaccine Optimism Wave).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>